{"id":6895,"date":"2025-02-19T09:59:32","date_gmt":"2025-02-19T14:59:32","guid":{"rendered":"https:\/\/www.wmfc.ca\/?p=6895"},"modified":"2025-03-02T11:35:08","modified_gmt":"2025-03-02T16:35:08","slug":"lessai-btk-degrader-recrute-maintenant-au-canada","status":"publish","type":"post","link":"https:\/\/www.wmfc.ca\/fr\/2025\/02\/19\/btk-degrader-trial-now-recruiting-in-canada\/","title":{"rendered":"Recrutement actif pour un essai clinique sur le d\u00e9gradeur de KTB (\"BTK\")  au Canada"},"content":{"rendered":"<p>Les Canadiens atteints de macroglobulin\u00e9mie de Waldenstr\u00f6m qui r\u00e9pondent aux crit\u00e8res d'inclusion pourraient envisager de participer \u00e0 une nouvelle \u00e9tude sur le BGB-16673 de Beigene, un d\u00e9gradeur de prot\u00e9ines ciblant la tyrosine kinase de Bruton.  Pour vous aider \u00e0 comprendre ce qu'est un d\u00e9gradeur de BTK, <a href=\"\/fr\/2025\/02\/18\/inhibiteurs-de-btk-vs-degradateurs-de-btk\/\">voir notre r\u00e9cent article<\/a> en les comparant aux inhibiteurs de BTK (BTKi).<\/p>\n<p>Titre officiel de l'\u00e9tude : \u00c9tude de phase 1\/2, ouverte, d'escalade de dose et d'expansion du Bruton Tyrosine Kinases Targeted Protein Degrader BGB-16673 chez des patients atteints de tumeurs malignes \u00e0 cellules B.<\/p>\n<p>Les lieux d'\u00e9tude canadiens qui recrutent actuellement sont :<\/p>\n<ul>\n<li><strong>Calgary<\/strong>(AB) : Arthur Child Comprehensive Cancer Centre<\/li>\n<li><strong>Edmonton<\/strong>(AB) : Cross Cancer Institute<\/li>\n<li><strong>Qu\u00e9bec<\/strong>QU\u00c9BEC, QC :  Universit\u00e9 de Laval, H\u00f4pital de l'enfant J\u00e9sus, Centre Int\u00e9gr\u00e9 de Canc\u00e9rologie<\/li>\n<li><strong>Vancouver<\/strong>(Colombie-Britannique) : British Columbia Cancer Agency, Vancouver Centre<\/li>\n<li><strong>Toronto<\/strong>(ON) :  Princess Margaret Cancer Centre<\/li>\n<\/ul>\n<p>Pour en savoir plus, consultez le site <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05006716\" target=\"_blank\" rel=\"noopener\">Description de l'essai sur le site des NIH<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Canadians with Waldenstr\u00f6m\u2019s Macroglobulinemia who meet inclusion requirements may want\u00a0to consider participation in a new study of Beigene\u2019s BGB-16673, a Bruton Tyrosine Kinase\u00a0Targeted Protein Degrader.\u00a0 To help in your understanding of a BTK Degrader, see our recent post comparing them to BTK inhibitors (BTKi). O\ufb03cial title of the study: A Phase 1\/2, Open-Label, Dose Escalation and Expansion Study of\u00a0the Bruton Tyrosine Kinases Targeted Protein Degrader BGB-16673 in Patients with B-cell\u00a0Malignancies. Canadian Study Locations Now Recruiting: Calgary, AB:\u00a0 Arthur Child Comprehensive Cancer Centre Edmonton, AB:\u00a0 Cross Cancer Institute Qu\u00e9bec, QC:\u00a0 Universit\u00e9 de Laval, H\u00f4pital de l\u2019enfant J\u00e9sus, Centre Integre de Cancerologie Vancouver, <a href=\"https:\/\/www.wmfc.ca\/fr\/2025\/02\/19\/btk-degrader-trial-now-recruiting-in-canada\/\"> [&#8230;]<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-6895","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/6895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/comments?post=6895"}],"version-history":[{"count":3,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/6895\/revisions"}],"predecessor-version":[{"id":6913,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/6895\/revisions\/6913"}],"wp:attachment":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/media?parent=6895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/categories?post=6895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/tags?post=6895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}